Litcius/Paper detail

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

Egbert F. Smit, Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares, Jose M. Pacheco, Bob T. Li, David Planchard, Christina S. Baik, Yasushi Goto, Haruyasu Murakami, Andreas Saltos, Kaline Pereira, Ayumi Taguchi, Yingkai Cheng, Qi Yan, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne

2024The Lancet Oncology157 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTrastuzumabCohortInternal medicineClinical endpointOncologyLung cancerCancerClinical trialBreast cancerHER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPeptidase Inhibition and Analysis